Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Notes Payables (2019 - 2022)

Opus Genetics has reported Notes Payables over the past 3 years, most recently at $215000.0 for Q1 2022.

  • Quarterly Notes Payables changed N/A to $215000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $215000.0 through Mar 2022, changed N/A year-over-year, with the annual reading at $538000.0 for FY2021, N/A changed from the prior year.
  • Notes Payables was $215000.0 for Q1 2022 at Opus Genetics, down from $538000.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $5.0 million in Q4 2019 and troughed at $215000.0 in Q1 2022.
  • The 3-year median for Notes Payables is $538000.0 (2021), against an average of $1.9 million.